How KPV works
An alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial.
Also called: Lys-Pro-Val, Lysine-proline-valine, alpha-MSH(11-13), KPV acetate.
Anti-inflammatory and antimicrobial peptides · C-terminal alpha-MSH tripeptide with preclinical anti-inflammatory activity · Evidence: Animal studies only.
KPV can enter gut and immune cells through a small-peptide transporter called PepT1. In laboratory work it turns down some inflammation signals. It is a fragment of alpha-MSH, but its effects do not require the same pigment-making signal.
- PepT1 / SLC15A1: Carries KPV into gut and immune cells in laboratory experiments.
- NF-kappaB and MAPK: KPV reduced these inflammation signals in cells.
- MC1R: Mouse anti-inflammatory effects were partly independent of this pigment-related receptor.
Half-life: Unknown in humans; no published human pharmacokinetic study was found.
Related to KPV
- LL-37: A human defense peptide with mixed topical wound-trial results and no established injection regimen.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Evaluation of KPV-related Bulk Drug Substances (KPV (free base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List, FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Ulcerative colitis, NHS · 2026
- Unapproved peptide product promoters and suppliers are put on notice, Therapeutic Goods Administration · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.